M-14019 Pepsinogen II (PG II) Quantitative Test Kit
Clinical Significance: PGII (Pepsinogen II) is highly correlated with fundic mucosal lesions (as opposed to antral mucosa). Elevated PGII levels are associated with fundic gland atrophy, gastric epithelial metaplasia or pseudopyloric metaplasia, and dysplastic hyperplasia. The progressive decrease in the PGI/II ratio is related to the progression of gastric mucosal atrophy. Therefore, measuring the ratio of PGI to PGII can serve as a "serological biopsy" of the fundic gland mucosa.
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
Usage Scenarios:
- Hospitals and Gastroenterology Departments: For diagnosing and monitoring fundic gland atrophy, gastric epithelial metaplasia, pseudopyloric metaplasia, and dysplastic hyperplasia by measuring PGII levels and the PGI/II ratio.
- Primary Care Clinics: For routine screening of patients with symptoms of gastric disorders to assess the health of the fundic gland mucosa.
- Diagnostic Laboratories: For routine testing of serum PGII levels and the PGI/II ratio as part of comprehensive assessments of gastric function and mucosal health.
- Cancer Screening Programs: For early detection of gastric mucosal changes that may indicate a higher risk of gastric cancer.
Suitable Countries and Regions:
- Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for comprehensive gastric health management and early detection of gastric disorders.
- Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving diagnostic capabilities for gastric health and expanding access to modern diagnostic tools.
- Global Health Programs: International health initiatives focused on enhancing the detection and management of gastric disorders in low-resource settings.